NR4A1 and ductal breast carcinoma in situ: This works well for aggressive breast cancers such as triple-negative breast cancer, but is not well suited for hormone receptor-positive luminal breast cancer and early stages of breast cancer such as ductal carcinoma in situ (DCIS).2